heart disease in pregnancy

in review 5 min read Updated 2026-10-19
heart disease in pregnancy

CO ↑30–50% (peaks late T2), HR ↑, SVR ↓ → stenotic lesions and pulmonary hypertension tolerated poorly; regurgitant lesions well. Highest-risk window = labour and the first 24–72 h postpartum (autotransfusion). mWHO 2.0 class II–III or higher → Pregnancy Heart Team from pre-conception (ESC 2025). Mechanical valves are the exception to “no warfarin in pregnancy”. Don’t withhold cardioversion or PCI because of pregnancy; valve surgery only if maternal life at risk and other options fail.

normal vs abnormal

normal in pregnancynever normal
resting HR ↑10–20, palpitations, mild exertional dyspnoeahypoxaemia, resting dyspnoea, PND
soft systolic ejection murmur (≤2/6), S3, venous humdiastolic murmur, loud/harsh systolic murmur
displaced apex, mild oedema, mildly ↑JVPsyncope on exertion, chest pain, progressive orthopnoea
ECG: left axis shift, small Q in III, T inversion III/V1–2sustained arrhythmia, new conduction disease
NT-proBNP normal (no pregnancy-specific cut-off; strong NPV)NT-proBNP clearly raised

risk stratification — mWHO 2.0 (ESC 2025)

classIM-relevant examplescare
I–IIisolated ectopics, most SVTs, repaired simple shunts, mild PS/MVPlocal hospital
II–IIIEF >45%, HCM without complications, mild MS, moderate AS, moderate regurgitation, Marfan without dilatation, BAV aorta <45 mmshared care + Pregnancy Heart Team
IIIEF 30–45%, mechanical valve, prior PPCM with ≤ mild residual impairment, prior SCAD or ACS, prior adverse pregnancy outcome needing admission, prior cancer-therapy cardiotoxicity, moderate MS, severe asymptomatic AS, sustained VT, Marfan aorta 40–45 mmexpert centre, Pregnancy Heart Team-led
IV — contraindicatedPAH, EF <30% or NYHA III–IV, prior PPCM with > mild residual impairment, severe MS, severe symptomatic AS, Marfan aorta >45 mm (BAV >50 mm), vascular EDS, Eisenmengeradvise against; shared decision on termination

Congenital lesions (Fontan, systemic RV, cyanotic CHD) → full table in the guideline; all need adult CHD/cardio-obstetrics.

Pre-pregnancy: TTE ± exercise test for all with known/suspected structural disease; intervene on symptomatic severe stenosis before conception (ACC/AHA I).


valve lesions

lesionproblemmanagement
mitral stenosis↑HR shortens diastole → ↑LA pressure → pulmonary oedema, AFβ1-blocker (metoprolol), cautious diuretic; AF → rate control + anticoagulation; refractory severe → percutaneous balloon commissurotomy; valve area <1.5 cm² → intervene before pregnancy
aortic stenosisfixed LVOT — can’t raise CO; preload-dependentavoid hypovolaemia and abrupt SVR drop (careful neuraxial); severe symptomatic despite medical therapy → BAV/TAVI may be considered (very selected); symptomatic severe AS → intervene before pregnancy
MR / AR↓SVR reduces regurgitant fractionusually tolerated; diuretics if congested

mechanical valves (AHA/ACC 2020, ESC)

Thrombotic complications 9–24%, bleeding 20–30%; event-free pregnancy with live birth only ~55–58%. Young women needing a prosthesis and contemplating pregnancy → bioprosthetic preferred. Cardio-obstetrics centre only.

warfarin doseT1 (6–12 wk)T2–T3
≤5 mg/dcontinue warfarin (IIa) or LMWHwarfarin
>5 mg/ddose-adjusted LMWH BID (IIa)warfarin (or LMWH)
  • LMWH: BID, anti-Xa 0.8–1.2 U/mL at 4–6 h (peak); trough monitoring too in many centres — fixed-dose LMWH is unsafe
  • Warfarin embryopathy dose-dependent (low risk at ≤5 mg/d); continue warfarin until pregnancy confirmed, switch before 6 wk if plan is LMWH
  • Delivery: switch VKA → LMWH/IV UFH at 36 wk or ≥2 wk before planned delivery; LMWH → IV UFH ≥36 h before; stop UFH ≥4–6 h before; labour on VKA → caesarean after reversal (foetal ICH risk)
  • Postpartum: restart UFH/LMWH at 6–12 h ; start warfarin only from 7–14 days (late bleeding) — breastfeeding-compatible
  • Valve thrombosis: TTE/fluoroscopy; obstructive → thrombolysis or surgery

arrhythmias

rhythmmanagement
PVCs / PACscommon; reassure if low burden + normal echo; symptomatic or high burden → metoprolol or bisoprolol; check CBC, ferritin, K⁺/Mg²⁺/Ca²⁺, TSH
SVTvagal → adenosine (safe) → β1-blocker or verapamil; prophylaxis with metoprolol; DCCV if unstable
AF/flutterlook for MS, thyrotoxicosis, CHD; rhythm control preferred — DCCV safe in all trimesters (foetal monitoring); rate control β-blocker ± digoxin; anticoagulate per CHA₂DS₂-VA (not validated in pregnancy) with LMWH
VTDCCV if unstable; β-blocker; sotalol/flecainide if needed; avoid amiodarone (foetal thyroid) unless life-threatening and refractory
AV blockusually congenital/structural; delivery vagal surges → monitor in labour
  • Cardioversion and defibrillation are safe at all stages (pads anterolateral, left uterine displacement)
  • Labetalol is an antihypertensive, not an antiarrhythmic of choice
  • Anticipate β-blocker down-titration postpartum (HR/BP fall)
PVCs in pregnancy

10% PVC burden, normal echo, symptomatic → metabolic labs, then metoprolol (or bisoprolol). Avoid atenolol (FGR) and amiodarone (foetal hypothyroidism); labetalol is for BP.

syncope

  • Vasovagal/orthostatic common (↓SVR, IVC compression)
  • Exertional, prolonged, or with palpitations/chest pain → ECG + echo; consider PE, arrhythmia, haemorrhage (abruption, ectopic early), AS/HCM/PAH

other

  • ACS: SCAD is the leading cause of pregnancy-associated MI (peripartum) — conservative if stable; ASA, β-blocker; PCI with radial access if ongoing ischaemia — see spontaneous coronary artery dissection
  • Aortic dissection: Marfan, Loeys–Dietz, bicuspid aortopathy, Turner, vEDS; β-blocker throughout; type A → surgery (with CS if viable)
  • Statins: FDA removed pregnancy contraindication (2021) — continue only in very high risk (FH, recent ACS) after discussion; stop for primary prevention ~3 months before conception; avoid in breastfeeding
  • Endocarditis prophylaxis: not routine for delivery; may be considered in high-risk women (ESC IIb)
drugs contraindicated in pregnancy

ACEi, ARB, ARNI, MRA, SGLT2i, ivabradine, amiodarone (except life-threatening), atenolol, DOACs, warfarin (except mechanical valves), statins (most), endothelin antagonists. Full table → prescribing in pregnancy and lactation.

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction heart disease in pregnancy